Molecular Profiling in NSCLC
Fabrice Barlesi, MD, discusses the importance of molecular testing in patients with nonsquamous non–small cell lung cancer during the World Conference on Lung Cancer in Toronto, Canada.
Fabrice Barlesi, MD, head of the Multidisciplinary Oncology and Therapeutic Innovations Department at Aix-Marseille University and the Assistance Publique Hôpitaux de Marseille, France, discusses the importance of molecular testing in patients with nonsquamous nonsmall cell lung cancer (NSCLC) during the World Conference on Lung Cancer (WCLC) in Toronto, Canada.
In this patient population, Barlesi recommends testing for at least 4 biomarkers, including EGFR, ALK, ROS1, and BRAF. He says there are now clear signs of efficacy with additional biomarkers, as well.
Barlesi says results were presented at this year’s WCLC meeting for patients withRET, NTRK, and TRK rearrangements. The field continues to grow rapidly with many approved drugs, as well some that have received a breakthroughdesignation from the FDA.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
